Chia Tai Tianqing: Steady Growth in the Future

In the past year, the market of the pharmaceutical sector has fluctuated, showing a trend of highs and lows as a whole.

Morgan Stanley recently pointed out in the analysis report "2022 Economic and Industry Outlook - China's Choice under Great Changes" that, unlike real estate and education, China's pharmaceutical industry has strong technological innovation attributes, which will certainly benefit people's livelihood and development.

Xie Chengrun, executive director of Sino Biopharmaceuticals and chairman of Chia Tai Tianqing, told reporters that the ultimate goal of policy reform in the medical industry is always to balance patients, medical insurance fund quotas and the development of innovative pharmaceutical companies on the premise of sustainable development of all parties.

Biopharmaceutical track emerges

On January 20, Chia Tai Tianqing's first biosimilar drug adalimumab injection was officially launched for the treatment of three major indications: rheumatoid arthritis, ankylosing spondylitis and psoriasis

In the field of biological drugs with high technical barriers, Chia Tai Tianqing has always had a rich product line layout, and is developing a number of innovative monoclonal antibodies, bispecific antibodies, and cell therapy products, including CD20-CD3 bispecific antibodies, BCMA-CD3 Bispecific antibodies, CD38 monoclonal antibodies, CD38-CD3 bispecific antibodies, cell therapy products,

In 2021, Chia Tai Tianqing ranked second in the TOP100 China Pharmaceutical R&D Comprehensive Strength Rankings released by the China Pharmaceutical R&D Innovation Summit, and Chia Tai Tianqing entered the top 10 for the first time in the TOP50 China Biopharmaceutical R&D Strength Rankings released at the same time

Innovative drugs enter the harvest period

In recent years, Chia Tai Tianqing has been building its own pipeline moat in the way of "self-research + cooperation", and has made substantial progress in innovation and transformation

Currently, the Chia Tai Tianqing Research Institute is carrying out 135 clinical trials, of which 110 are clinical trials of innovative drugs, accounting for 81%; in 2021, the research institute has established a total of 42 new projects, of which 41 are innovative drugs, accounting for an absolute proportion

Xie Chengrun said that no matter how the industry changes, Chia Tai Tianqing has always adhered to the original intention of the pharmaceutical people, adhered to the orientation of clinical needs, and made innovative drugs that are differentiated and centered on patient needs.